Domestic and foreign pharmaceutical companies are speeding up the development of new drugs for the rare Fabry disease. They aim to develop treatments that improve not only efficacy and safety but also administration methods compared to existing treatments.

According to industry sources on the 15th, the Ministry of Food and Drug Safety recently approved the Phase I/II clinical trial plan (IND) for LA-GLA, a new drug candidate for Fabry disease being jointly developed by GC Biopharma and Hanmi Pharmaceutical. The two companies entered multinational clinical trials in August last year after receiving approval in the U.S. and Korea.

Fabry disease is a rare disease that is inherited as a sex